Important: Investors must purchase shares before the respective record date (considering settlement timelines) to qualify for the declared dividend. Shares must be reflected in the demat account as of the record date to receive the payout.
📌 Stock Split Scheduled
A stock split is also on the calendar this week.
| Company | Split Ratio | Face Value (Old) | Face Value (New) | Record Date |
| Titan Biotech Ltd | 1:5 | ₹10 | ₹2 | February 20, 2026 |
A 1:5 split means each existing share of ₹10 face value will be subdivided into five shares of ₹2 each. The total investment value remains unchanged, but the number of shares increases proportionately.
Shareholders holding the stock on the record date will see the revised share count automatically updated in their demat accounts.
📌 Bonus Issues Announced
Two companies have scheduled bonus share issuances this week.
| Company | Bonus Ratio | Explanation | Record/Ex-Date |
| Riddhi Steel and Tube Ltd | 1:2 | 1 bonus share for every 2 shares held | February 17, 2026 |
| Bazel International Ltd | 1:1 | 1 bonus share for every 1 share held | Ex-bonus: February 19, 2026 |
Bonus shares are issued free of cost to eligible shareholders. Investors must hold the shares before the record date (or prior to the ex-bonus date) to qualify. The additional shares are credited directly to the demat account.
Summary
The coming week presents multiple corporate action triggers across dividends, a stock split, and bonus share issuances. Key names such as Torrent Pharmaceuticals, Coal India, HAL, IRCTC, and PFC are offering dividend payouts, while Titan Biotech is executing a stock split. Meanwhile, Riddhi Steel and Bazel International have lined up bonus issuances.
Investors focused on dividend income or strategic corporate action opportunities should closely monitor the respective record and ex-dates to ensure eligibility. Proper timing of purchases remains crucial for participation in these benefits.
This article is intended solely for educational and informational purposes. The securities or companies mentioned are provided as examples and should not be considered as recommendations. Nothing contained herein constitutes personal financial advice or investment recommendations. Readers are advised to conduct their own research and consult a qualified financial advisor before making any investment decisions.
Investments in securities markets are subject to market risks. Please read all related documents carefully before investing.